Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.49 |
| ▸ | TLR2 | O60603 | 2/20 | 0.49 |
| ▸ | MDM4 | O15151 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20732318 | 1.00 | PTPN1 (0.49) | PTPN1TLR2MDM4TP53KMT2A | |
| SCHEMBL20732316 | 1.00 | PTPN1 (0.49) | PTPN1TLR2MDM4TP53KMT2A | |
| SCHEMBL31133584 | 1.00 | PTPN1 (0.49) | PTPN1TLR2MDM4TP53KMT2A | |
| SCHEMBL22069859 | 1.00 | PTPN1 (0.49) | PTPN1TLR2MDM4TP53KMT2A | |
| SCHEMBL30779239 | 1.00 | PTPN1 (0.49) | PTPN1TLR2MDM4TP53KMT2A | |
| SCHEMBL23463699 | 0.97 | TLR2 (0.53) | PTPN1TLR2MDM4TP53KMT2A | |
| SCHEMBL30069166 | 0.97 | TLR2 (0.53) | PTPN1TLR2MDM4TP53KMT2A | |
| SCHEMBL24729097 | 0.97 | TLR2 (0.53) | PTPN1TLR2MDM4TP53KMT2A | |
| SCHEMBL29162900 | 0.97 | TLR2 (0.53) | PTPN1TLR2MDM4TP53KMT2A | |
| SCHEMBL1709129 | 0.96 | KMT2A (0.52) | PTPN1TLR2MDM4TP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312419-B2 | Hemiasterlin derivative having cysteine residue | Sumitomo Pharma Co., Ltd. (JP) | 2025-05-27 | — | — | US | disclosed |
| EP-3666787-B9 | ANTIBODY-DRUG CONJUGATES INCLUDING HEMIASTERLIN DERIVATIVE | SUMITOMO PHARMA CO LTD (JP) | 2024-08-28 | — | — | EP | disclosed |
| US-20240059732-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | Sumitomo Pharma Co., Ltd. (JP) | 2024-02-22 | — | — | US | disclosed |
| EP-3666787-B1 | ANTIBODY-DRUG CONJUGATES INCLUDING HEMIASTERLIN DERIVATIVE | SUMITOMO PHARMA CO LTD (JP) | 2024-02-21 | — | — | EP | disclosed |
| US-11795195-B2 | Antibody-drug conjugates including hemiasterlin derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-24 | — | — | US | disclosed |
| US-20220144889-A1 | Hemiasterlin Derivative Having Cysteine Residue | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-05-12 | — | — | US | disclosed |
| EP-3925668-A1 | HEMIASTERLIN DERIVATIVE HAVING CYSTEINE RESIDUE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2021-12-22 | — | — | EP | disclosed |
| CN-113412271-A | Hamiltrin derivatives having cysteine residue | 大日本住友制药株式会社 | 2021-09-17 | — | — | CN | disclosed |
| WO-2020166600-A1 | HEMIASTERLIN DERIVATIVE HAVING CYSTEINE RESIDUE | 大日本住友製薬株式会社 | 2020-08-20 | — | — | WO | disclosed |
| US-20200247847-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-06 | — | — | US | disclosed |
| EP-3666787-A1 | ANTIBODY-DRUG CONJUGATES INCLUDING HEMIASTERLIN DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| CN-111032676-A | Antibody drug complex comprising a hemiasterlin derivative | 大日本住友制药株式会社 | 2020-04-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144889-A1 | Hemiasterlin Derivative Having Cysteine Residue | SHBG, CYP11A1, CYP11B1 | PTPN1 2233/4885TLR2 4139/4885MDM4 2803/4885 |
| US-12312419-B2 | Hemiasterlin derivative having cysteine residue | SHBG, CYP11A1, CYP11B1 | PTPN1 2233/4885TLR2 4139/4885MDM4 2803/4885 |
| US-11795195-B2 | Antibody-drug conjugates including hemiasterlin derivative | HSD3B2, HSD3B1, HSD11B2 | PTPN1 1524/4885TLR2 4347/4885MDM4 4109/4885 |
| US-20240059732-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | HSD3B2, HSD3B1, HSD11B2 | PTPN1 1524/4885TLR2 4347/4885MDM4 4109/4885 |
| US-20200247847-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | HSD3B2, HSD3B1, HSD11B2 | PTPN1 1524/4885TLR2 4347/4885MDM4 4109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.